PSMA-HBED与PSMA-I&T作为前列腺癌诊断药物的比较
19例前列腺癌患者在2周内先后接受68Ga-PSMA-HBED与PSMA-I&T PET-CT显像,共分析47个PSMA摄取病灶;PSMA-HBED的整体病灶结合(SUVpeak)显著高于PSMA-I&T,左心室血池与骨髓本底SUVmean在PSMA-I&T更高;除2个小于4 mm的淋巴结病灶仅在PSMA-HBED显示外,其余病灶一致(96%)。作者认为PSMA-HBED可能具有略高的诊断准确性。
要点
- 19例前列腺癌患者2周内先后行PSMA-HBED与PSMA-I&T PET-CT,共47个病灶。
- PSMA-HBED整体病灶SUVpeak显著高于PSMA-I&T(配对t检验,p=0.0001)。
- 2个小于4 mm淋巴结病灶仅PSMA-HBED显示,其余病灶一致(96%)。
核心结论
- 患者自身对照显像显示PSMA-HBED的病灶结合高于PSMA-I&T,PSMA-HBED可能具有更好的病灶对比度。
- 96%的病灶在两药间一致,但2个小于4 mm的淋巴结病灶经PSMA-HBED显示而PSMA-I&T判为正常。
- 作者认为上述发现提示PSMA-HBED相比PSMA-I&T具有略高的诊断准确性。
研究设计与样本
- 19例因前列腺癌转诊行68Ga-PSMA显像的患者,在2周内先后接受PSMA-HBED与PSMA-I&T PET-CT显像。
- 两种药物均采用点击化学合成,显像在同一台Siemens Biograph mCT上按相同标准化方法完成。
- 病灶分析纳入所有被认为可能或确定代表前列腺癌的PSMA结合部位,比较病灶一致性与病灶结合效率(SUVpeak)。
- 按患者测定左心室腔血池、骨、肌肉与肝脏的SUVmean作为图像本底指标。
主要发现
- 全部患者共观察到47个PSMA摄取病灶:骨病灶10个、淋巴结病灶19个、高级别前列腺内结合18个。
- 除2个小于4 mm的淋巴结病灶未在PSMA-I&T显像中显示外,其余病灶在两药间一致。
- SUVpeak评估显示PSMA-HBED的整体病灶结合显著高于PSMA-I&T(配对t检验,p=0.0001)。
- 左心室血池与骨髓SUVmean在PSMA-I&T显著高于PSMA-HBED(配对t检验,血池p<1×10-5,骨髓p<0.005)。
关键数值与推荐
- 病灶一致性分析:47个病灶中除2个小于4 mm淋巴结病灶外均一致,即一致比例为96%。
- 病灶结合效率:PSMA-HBED整体病灶SUVpeak显著高于PSMA-I&T(配对t检验,p=0.0001)。
- 本底:左心室血池SUVmean在PSMA-I&T显著高于PSMA-HBED(配对t检验,p<1×10-5),骨髓SUVmean在PSMA-I&T显著高于PSMA-HBED(配对t检验,p<0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The 68Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes. In this study, we examine whether PSMA-I&T has comparative efficacy, such that it could replace PSMA-HBED as a diagnostic agent in prostate carcinoma. METHODS: 19 patients with PCa referred for 68Ga-PSMA imaging were imaged with PSMA-HBED and PSMA-I&T PET-CT imaging within a 2-week period. The two pharmaceuticals were synthesised using click chemistry. Imaging was performed using the same standardised methodology on a Siemens Biograph mCT. All sites of PSMA binding thought to represent PCa (probable or definite) were included in a lesion analysis that examined lesion concordance and lesional binding efficiency (SUVpeak) between the two radiopharmaceuticals. For each patient, SUVmean of the LV cavity blood pool, bone, muscle and liver were determined as image background measures. RESULTS: Across all patients, PSMA uptake was observed in 47 lesions (10 bone lesions, 19 nodal lesions, 18 high-grade intraprostatic binding). Lesions were concordant between the agents in all except for two small (<4 mm) nodal lesions which were not visualised with PSMA-I&T. SUVpeak assessment showed significantly greater overall lesion binding with HBED (paired t test, p = 0.0001). LV blood pool and bone marrow SUVmean were significantly higher for I&T than HBED (paired t test, blood pool p < 1 × 10-5, bone marrow p < 0.005). CONCLUSION: Intra-patient comparative imaging demonstrates higher lesional PSMA-HBED binding than PSMA-I&T and that the HBED agent is likely to have better lesion contrast. While there was concordance in 96% of lesions, 2 small nodal lesions were appreciated with PSMA-HBED imaging while considered normal with PSMA-I&T. These findings suggest that HBED-PSMA has a slightly higher diagnostic accuracy in comparison to PSMA-I&T.
引用
- McCarthy M, Langton T, Kumar D, et al. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nucl Med Mol Imaging. 2017. PMID: 28474140. doi:10.1007/s00259-017-3699-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。